TC Biopharm (Holdings) Yönetim

Yönetim kriter kontrolleri 3/4

TC Biopharm (Holdings) CEO'su Bryan Kobel, Jun2021 tarihinde atandı, in görev süresi 3.42 yıldır. in toplam yıllık tazminatı £ 427.17K olup, şirket hissesi ve opsiyonları dahil olmak üzere 83.3% maaş ve 16.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.44% ine doğrudan sahiptir ve bu hisseler $ 2.82K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.1 yıl ve 2.5 yıldır.

Anahtar bilgiler

Bryan Kobel

İcra Kurulu Başkanı

UK£427.2k

Toplam tazminat

CEO maaş yüzdesi	83.3%
CEO görev süresi	3.4yrs
CEO sahipliği	0.4%
Yönetim ortalama görev süresi	3.1yrs
Yönetim Kurulu ortalama görev süresi	2.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Bryan Kobel'un ücretlendirmesi TC Biopharm (Holdings)'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2024	n/a	n/a	-UK£9m
Dec 31 2023	UK£427k	UK£356k	-UK£6m
Sep 30 2023	n/a	n/a	-UK£4m
Jun 30 2023	n/a	n/a	-UK£2m
Mar 31 2023	n/a	n/a	-UK£2m
Dec 31 2022	UK£436k	UK£363k	-UK£1m

Tazminat ve Piyasa: Bryan 'ın toplam tazminatı ($USD 554.56K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 651.15K ).

Tazminat ve Kazançlar: Bryan 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Bryan Kobel (45 yo)

3.4yrs

Görev süresi

UK£427,169

Tazminat

Mr. Bryan Leland Kobel serves as Chief Executive Officer at TC Biopharm Limited. Mr. Kobel serves as Chief Executive Officer of TC Biopharm (Holdings) Plc since June 2021 and serves as Director. He joined...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Bryan Kobel	CEO & Director	3.4yrs	UK£427.17k	0.44% $ 2.8k
Martin Thorp	CFO & Director	5.7yrs	UK£322.02k	0.00018% $ 1.2
Christopher Camarra	Executive Vice President of Communications	2.8yrs	Veri yok	Veri yok
Lauren Bor	Head of Commercial Development Division	less than a year	Veri yok	Veri yok

3.1yrs

Ortalama Görev Süresi

Deneyimli Yönetim: TCBP 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Bryan Kobel	CEO & Director	no data	UK£427.17k	0.44% $ 2.8k
Martin Thorp	CFO & Director	8.7yrs	UK£322.02k	0.00018% $ 1.2
Arlene Morris	Non-Executive Independent Chair	2.8yrs	UK£23.53k	0% $ 0
Mark Bonyhadi	Chairman of Scientific Advisory Board	2.5yrs	UK£23.53k	0% $ 0
A. Culverwell	Non-Executive Independent Director	2.8yrs	UK£23.53k	0% $ 0
Isabelle Riviere	Member of Scientific Advisory Board	2.1yrs	Veri yok	Veri yok
Daniel Olive	Member of Scientific Advisory Board	2.1yrs	Veri yok	Veri yok
Uma Lakshmipathy	Member of Scientific Advisory Board	2.5yrs	Veri yok	Veri yok
Erin Adams	Member of Scientific Advisory Board	2.5yrs	Veri yok	Veri yok
Blythe Sather	Member of Scientific Advisory Board	2.1yrs	Veri yok	Veri yok
Chris Bond	Member of Scientific Advisory Board	2.1yrs	Veri yok	Veri yok

2.5yrs

Ortalama Görev Süresi

70yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: TCBP 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.5 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

TC Biopharm (Holdings) Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

TC Biopharm (Holdings) Plc, Annual General Meeting, Mar 14, 2024

TC BioPharm (Holdings) PLC Appoints Lauren Bor as Head of Commercial Development Division

TC Biopharm (Holdings) Plc, Annual General Meeting, Jun 29, 2023

TC Biopharm Appoints Arlene Morris as New Chair of the Board

TC BioPharm (Holdings) plc Announces the Appointment of Bree Harlin as Chief Clinical Officer

High number of new and inexperienced directors

Recent updates

TC BioPharm Remains Compliant with All Nasdaq Listing Requirements and Continues Trading on the Nasdaq Stock Exchange, Responds to False Social Media Claim

TC BioPharm Remains Compliant with All Nasdaq Listing Requirements and Continues Trading on the Nasdaq Stock Exchange, Responds to False Social Media Claim

TC Biopharm (Holdings) Plc Announces Dosing of 5 New Patients in ACHIEVE

TC BioPharm (Holdings) PLC Announces Grant of European Patent Covering Use of Modified Gamma Delta Cells for the Treatment of Cancer and Viral Indications

TC Biopharm (Holdings) Plc has filed a Follow-on Equity Offering.

TC Biopharm (Holdings) Plc has completed a Follow-on Equity Offering in the amount of $2 million.

TC BioPharm (Holdings) PLC Announces Dosing of 6th Patient in ACHIEVE Study in Patients with Acute Myeloid Leukemia

TC Biopharm (Holdings) Plc has filed a Follow-on Equity Offering.

TC Biopharm (Holdings) Provides Non-Compliance Update

TC Biopharm (Holdings) Plc Announces Launch of Compassionate Use Program for TCB008

New major risk - Revenue size

TC Biopharm (Holdings) Plc, Annual General Meeting, Mar 14, 2024

TC Biopharm (Holdings) Plc has filed a Follow-on Equity Offering in the amount of $3.5 million.

TC BioPharm (Holdings) PLC Appoints Lauren Bor as Head of Commercial Development Division

TC Biopharm (Holdings) Plc Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia

TC Biopharm (Holdings) Plc Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia

New major risk - Share price stability

TC Biopharm (Holdings) Regains Compliance with the Nasdaq Stock Market Listing Rule 5550(b)

TC Biopharm (Holdings) Plc, Annual General Meeting, Jun 29, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

TC Biopharm Appoints Arlene Morris as New Chair of the Board

TC Biopharm (Holdings) Plc Announces Successful Dosing of Final Patient in ACHIEVE Safety Cohort

TC BioPharm (Holdings) plc Announces the Appointment of Bree Harlin as Chief Clinical Officer

TC Biopharm Receives Notice of Non-compliance with NASDAQ's Listing Rule 5550(b)(1)

First half 2022 earnings released: EPS: UK£0.93 (vs UK£6.78 loss in 1H 2021)

TC Biopharm (Holdings) Plc announced that it has received $7.35 million in funding

TC Biopharm (Holdings) Plc announced that it expects to receive $7.35 million in funding

Tc BioPharm Begins Dosing Phase 2B Clinical Study Evaluating Its Lead Compound, Omnimmune(R), in Patients with Acute Myeloid Leukemia

High number of new and inexperienced directors

TC Biopharm (Holdings) Plc, Annual General Meeting, Nov 14, 2022

TC Biopharm (Holdings) Plc Announces Additions to Scientific Advisory Board

TC Biopharm (Holdings) Plc, Annual General Meeting, Nov 01, 2022

TC Biopharm (Holdings) PLC Receives MHRA Approval for 18-Month Extrapolated Shelf-Life of Allogeneic Cell Therapy Product, OmnImmune

High number of new and inexperienced directors

TC Biopharm (Holdings) Plc has completed a Follow-on Equity Offering in the amount of $4 million.

TC Biopharm Announces Formation of Scientific Advisory Board

TC Biopharm (Holdings) Plc Receives CryoTC Trademark for Proprietary Cell Freezing Process

High number of new directors

TC Biopharm (Holdings) Plc Announces Positive Phase 1b/2a Data in Late-Stage Acute Myeloid Leukemia Patients Treated with Allogeneic Gamma Delta T Cells

TC Biopharm (Holdings) Plc Announces Appointment of New Board Members

TC Biopharm (Holdings) Plc has completed an IPO in the amount of $17.54118 million.

No independent directors

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş